No vac­cine bid un­til af­ter vote, Pfizer says

San Francisco Chronicle - - CORONAVIRU­S PANDEMIC -

Pfizer Inc. can­not re­quest emer­gency au­tho­riza­tion of its COVID19 vac­cine be­fore the third week of Novem­ber — and that’s if ev­ery­thing goes well, CEO Al­bert Bourla said Fri­day.

De­spite Pres­i­dent Trump’s re­peated prom­ises of a vac­cine be­fore elec­tion day, sci­en­tists have been cau­tion­ing that it’s un­likely data show­ing a lead­ing shot ac­tu­ally works would come un­til Novem­ber or De­cem­ber.

An­other lead­ing U.S. con­tender, Moderna Inc., pre­vi­ously an­nounced the ear­li­est it could seek au­tho­riza­tion of its own vac­cine would be Nov. 25.

To qual­ify for an “emer­gency use au­tho­riza­tion,” any COVID19 vac­cine must track at least half the par­tic­i­pants in largescale stud­ies for two months af­ter their sec­ond dose, the time pe­riod in which side ef­fects are likely to ap­pear. Bourla es­ti­mated Pfizer’s 44,000per­son study will reach that mile­stone in mid­novem­ber.

“We are op­er­at­ing at the speed of sci­ence,” he wrote in a let­ter posted to the com­pany’s web­site.

The vac­cine made by Pfizer and its Ger­man part­ner Bion­tech are among sev­eral lead­ing can­di­dates in fi­nal test­ing.

Even if a vac­cine emerges by year’s end, only lim­ited doses will be avail­able right away. The U.S. govern­ment is de­cid­ing who would be first in line, al­most cer­tainly health care work­ers, and es­ti­mates there may be enough for wide­spread vac­ci­na­tions in the spring.

Pablo Martinez Mon­si­vais / As­so­ci­ated Press 2019

Al­bert Bourla, chief ex­ec­u­tive of­fi­cer of Pfizer, ap­pears at a Se­nate hear­ing last year.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.